SYGNIS Signs Initial Distribution Agreement with FUNAKOSHI
News Mar 05, 2015
SYGNIS AG has announced that it has signed an non-exclusive distribution agreement for SYGNIS’ TruePrime™ family with FUNAKOSHI Co. Ltd. for the Japanese market.
With this agreement, SYGNIS grants FUNAKOSHI the non-exclusive rights to promote, market and sell all existing as well as future products for DNA and RNA amplification from smallest amounts of samples down to single cells for applications such as next generation sequencing (NGS) in Japan.
SYGNIS’ TruePrime™ product family is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology for the amplification of various DNA or RNA species for a multitude of applications.
As a leading solution provider, FUNAKOSHI is offering a broad portfolio of quality research reagents as well as high-tech instruments in the wide fields of molecular biology, protein research, cell biology and diagnostics to customers all over Japan.
“We are very pleased about this distribution agreement for our proprietary product portfolio with FUNAKOSHI, an important gatekeeper in Japan, the second largest life science market in the world today. With its wide customer network focused on molecular biology and diagnostics, FUNAKOSHI is best positioned to leverage the benefits of our existing as well as future products to customers in molecular biology especially in the fast growing field of NGS in Japan,” Pilar de la Huerta, CEO and CFO of SYGNIS commented.
Huerta continued, “After we successfully signed distributions agreements for North America and Europe, we today were able to sign the initial agreement for the Asian markets. We are very focused and committed to building up and expanding our distribution channel program in 2015 and only just have started with our extensive marketing activities in order to make our product widely available.”
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE